- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Life Science & Biotech
Ex-Dow Agro scientist receives seven years for economic espionage
December 21, 2011
Kexue Huang was sentenced after pleading guilty in October to sending Dow AgroSciences trade secrets to China and Germany.
MoreEx-Dow Agro scientist set to be sentenced in espionage case
December 21, 2011
Scott OlsonFederal prosecutors are recommending that Kexue Huang be sentenced to 87 months in prison for sending trade secrets worth
millions to China and Germany.
MoreSEC accuses Positron CEO of misleading investors
November 28, 2011
Chris O'MalleyRegulators allege CEO Patrick G. Rooney diverted millions of dollars from a hedge fund into the struggling Fishers company
without investors' knowledge.
MorePurdue courts Silicon Valley partnerships
November 26, 2011
Chris O'MalleyThe office, at NASA Ames Research Center, in Mountain View, Calif., aims to commercialize Purdue-developed technology through
partnerships with private industry.
MoreJONES: Patent reform is mixed bag for life sciences companies
November 26, 2011
Kristin Jones / Special to IBJFor Indiana's life sciences sector, the change both raises hopes and creates challenges for continued growth.
MoreCancer-drug firm Endocyte to build commercial team in Indianapolis
November 12, 2011
J.K. WallEndocyte employs 12 people in Indianapolis and plans to add three or four more commercial executives there over the next year
and a half as it anticipates approval of its ovarian cancer medication in Europe.
MoreDrug shortages hit Lilly, Endocyte
November 7, 2011
J.K. WallThe nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co.
and Endocyte Inc.
MoreOrtho firms pull back on doc payments
October 31, 2011
J.K. WallThe number of payments in excess of $1 million didn’t change substantially from year to year, but orthopedic companies
sharply cut their fees to surgeons who received the smallest amounts.
MoreInsurer Humana's quarterly profit climbs 13 percent
October 31, 2011
Associated PressHumana Inc. raised its 2011 earnings forecast, following the lead set by other big insurers, including competitor WellPoint
Inc.
MoreDrug theft is ongoing battle for pharmacies
October 29, 2011
Chris O'MalleyOver the last 12 months, the Indiana Board of Pharmacy has conducted license litigation involving at least 35 pharmacy personnel
statewide who've been accused of stealing drugs from work.
MoreIndiana software firm growing with life sciences focus
October 29, 2011
Katie MaurerRND Group fills development gaps for companies.
MoreDow Agro improves quarterly revenue, profit
October 27, 2011
IBJ Staff and Bloomberg NewsIndianapolis-based Dow AgroSciences on Thursday reported record third-quarter sales of $1.2 billion, up 27 percent from the
same period a year ago.
MoreBioCrossroads seeds upstart medical device maker
October 20, 2011
Chris O'MalleyBioCrossroads’ Indiana Seed Fund has invested $300,000 in a startup company chaired by a former Eli Lilly and Co. executive
developing an absorbable stent.
MoreProfit falls at Lilly but meets Wall Street expectations
October 20, 2011
J.K. WallThe Indianapolis-based drugmaker earned $1.24 billion in the three months ended Sept. 30, down 5 percent from the same quarter
a year ago, even as revenue surged 9 percent.
MoreEx-Dow Agro scientist pleads guilty in espionage case
October 18, 2011
IBJ Staff and Associated PressKexue Huang faces up to 13 years in prison after pleading guilty Tuesday morning to sending trade secrets worth millions to
China and Germany.
MoreQ&A
October 17, 2011
J.K. WallSherry Keramidas, who earned her doctorate in neuroscience and physiological psychology from Purdue University,
is executive director of the Maryland-based Regulatory Affairs Professionals Society, which is holding its annual conference
Oct. 22-26 at the Indiana Convention Center.
MoreCook Medical gets FDA panel's backing for stent
October 13, 2011
Bloomberg NewsThe device would be the first drug-coated stent approved in the U.S. to treat peripheral vascular disease in the largest artery
of the upper leg.
MoreFDA: Cook Medical’s stent met efficacy, safety goals
October 11, 2011
Bloomberg NewsPeripheral vascular devices, including stents, angioplasty balloons and synthetic grafts, generated $4.3 billion in global
revenue last year and may earn $5.6 billion in 2014.
MoreBiocrossroads lands $2.8 million Lilly Endowment grant
October 8, 2011
IBJ StaffThe advocate for the state's life sciences industry has now pulled in more than $25 million from the endowment.
MoreCook family provides funding for Rose-Hulman bioscience lab
October 1, 2011
IBJ StaffThe $500,000 gift will help further a decade-long expansion of the school's life sciences curriculum.
MoreFederal judge nixes firm's Bio Cremation lawsuit
September 27, 2011
Associated PressA federal judge in Pittsburgh has thrown out a lawsuit filed by a Pittsburgh company that claimed its so-called "Bio
Cremation" service — a flameless process to cremate remains — was being unfairly targeted by two Indiana
competitors.
MoreLilly's Alimta get favorable opinion for new use in Europe
September 26, 2011
J.K. WallIf approved for continuation maintenance, Eli Lilly and Co.'s Alimta could be used for longer stretches in lung cancer patients,
generating more revenue.
MoreRoche hopes to prosper from austerity
September 19, 2011
J.K. WallExecutives at Roche Diagnostics expect the wave of austerity measures being taken by western governments—including the
United States—to as much as double its sales of fluid- and DNA-based tests in the next three years.
MoreEx-Dow Agro scientist makes plea in trade-secret case
September 15, 2011
Associated PressA former Indiana scientist has agreed to plead guilty to charges of illegally sending trade secrets worth $300 million to
China and Germany.
MoreAIT's Evans gave $48M to start Marian med school
August 24, 2011
J.K. WallMarian disclosed Evans’ 2010 donation Wednesday as it held a groundbreaking ceremony for its medical and nursing school
building, which will be called the Michael A. Evans Center for Health Sciences.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
So the Mayor adds another non value added layer to having a vehicle towed? Whereby the City Government RECIEVES AN ILLEGAL KICKBACK FROM A LGOISTICS COMPANY THAT SUBS THE WORK TO LOCAL TOW COMPANIES? What is the service the City performs for receiving the "tribute"? This is RICO!!!!! What a corrupt and unnecessary layer. What a dirtbag Mayor and his cronies.
Owner occupied housing. Clear enough?
So people think I am paranoid. It's from experience in dealing with puds requested by developers who make major donations themselves to representatives, have nice fund raisers for those running for office and hide through pac's. then there are the public relation firms. You will note some pr comments below. You there Clyde Lee? My opinion. Commercial along 421, great. Multifamily housing, terrible idea that will change the town. Senior condos or zero lot line homes west, great. I suggest keeping all entries to commercial areas at 421. All entries to owner occupied on sycamore. Will keep the traffic on sycamore down some. Two other things. You can't trust what will be there in 10 years. Steve builds quality stuff, but areas change over time. Look at the changes at the wall mart center at 86th and 421 over the last 10 years. Look at the apartments and neighborhoods behind St Vincent's. Raintree properties WILL decrease in value if commercial and multifamily goes in near. It has already been happening around the bridges area. The houses that have been sold recently are way below market. Several deals not closed due to the Illinois construction and the whole unsurety of the bridges. It's pretty simple, Zionsville will approve the whole thing because the city council has been groomed over a LONG period of time for this. I might even suggest some are in their position as a result of this.
Esta, do you have a dog in this fight? You seem to really want to knock anyone against this project. No, I didn't move to Indiana for the architecture. I moved here for that red barn in the field. The horses and fields of corn. A place that is NOT overdeveloped. There are plenty of nearby places in Indianapolis that could be REDEVELOPED instead.
RKW - OK, we get it, you're paranoid. The question is, are you paranoid enough? Greg - Yes, Pittman(s) is (are) at it again. They are developers, they build things. It's what they do. So when you go to work tomorrow, Greg, you're at it again too. Cliff - Really? You moved to Indiana for its progressive architecture? That's like moving to England for the cuisine. Zionsvillain - The house you moved to was once a field or woods. I'm willing to bet folks were upset when that ground was plowed under and a house was built. But I guess now that you are in, everything should stop? "My house was OK, but the next one is sprawl." SE Guy - Please don't paint us with such a wide brush. Most reasonable Zionsville residents welcome planned, measured development.